Vemurafenib Interactions
There are 623 drugs known to interact with vemurafenib, along with 7 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 228 are major, 374 are moderate, and 21 are minor.
- View all 623 medications that may interact with vemurafenib
- View vemurafenib alcohol/food interactions (1)
- View vemurafenib disease interactions (7)
Most frequently checked interactions
View interaction reports for vemurafenib and the medicines listed below.
- Abraxane (paclitaxel protein-bound)
- Activated Charcoal (charcoal)
- Adriamycin (doxorubicin)
- Aspirin Low Strength (aspirin)
- Avastin (bevacizumab)
- Casodex (bicalutamide)
- Co-trimoxazole (sulfamethoxazole / trimethoprim)
- Coenzyme Q10 (ubiquinone)
- Colace (docusate)
- Compazine (prochlorperazine)
- Copper (copper gluconate)
- Dextrose (glucose)
- Diltiazem Hydrochloride SR (diltiazem)
- Dulcolax Stool Softener (docusate)
- Fentanyl Transdermal System (fentanyl)
- L-Arginine (arginine)
- L-Carnitine (levocarnitine)
- L-Cysteine (cysteine)
- Lithium Carbonate ER (lithium)
- Lovenox (enoxaparin)
- Metoprolol Succinate ER (metoprolol)
- Metoprolol Tartrate (metoprolol)
- Paracetamol (acetaminophen)
- Valproate Sodium (valproic acid)
- Vitamin B1 (thiamine)
- Vitamin B12 (cyanocobalamin)
- Vitamin B6 (pyridoxine)
- Vitamin D3 (cholecalciferol)
- Vitamin K (phytonadione)
- Vitamin K2 (menaquinone)
Vemurafenib alcohol/food interactions
There is 1 alcohol/food interaction with vemurafenib.
Vemurafenib disease interactions
There are 7 disease interactions with vemurafenib which include:
- lung toxicity
- cutaneous malignancies
- dermatological reactions
- hepatic impairment
- QT prolongation
- renal impairment
- visual complications
Report options
More about vemurafenib
- vemurafenib consumer information
- Compare alternatives
- Reviews (4)
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Mekinist
Mekinist is used to treat melanoma, non-small cell lung cancer, thyroid cancer, solid tumors, and ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Zelboraf
Zelboraf (vemurafenib) is used to treat skin cancer (metastatic melanoma). Includes Zelboraf side ...
Dacarbazine
Dacarbazine systemic is used for hodgkin's lymphoma, melanoma, melanoma, metastatic
Ipilimumab
ipilimumab (Yervoy) is an immunotherapy used for melanoma, renal cell carcinoma, non-small cell ...
Dabrafenib
Dabrafenib systemic is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
